Amelioration of Cerebral Ischemic Injury by a Synthetic Seco-nucleoside LMT497.
- Author:
Sangwoo RYU
1
;
Joonha KWON
;
Hyeon PARK
;
In Young CHOI
;
Sunyoung HWANG
;
Veeraswamy GAJULAPATI
;
Joo Young LEE
;
Yongseok CHOI
;
Katia VARANI
;
Pier Andrea BOREA
;
Chung JU
;
Won Ki KIM
Author Information
- Publication Type:Original Article
- Keywords: cerebral ischemia; MCAO; oxidative stress; inflammation; LMT497; Cl-IB-MECA
- MeSH: Animals; Brain; Brain Infarction; Brain Ischemia; Edema; Infarction, Middle Cerebral Artery; Inflammation; Ischemia; Microglia; Neurons; Oxidative Stress; Rats; Reactive Oxygen Species; Receptors, Purinergic P1; Reperfusion; Stroke; Superoxide Dismutase; Tissue Plasminogen Activator
- From:Experimental Neurobiology 2015;24(1):31-40
- CountryRepublic of Korea
- Language:English
- Abstract: Recently, we reported that the A3 adenosine receptor (A3AR) agonist LJ529 (2-chloro-N6-(3-iodobnzyl)-5'-N-methylcarbamoyl-4'-thioadenosine) reduces cerebral ischemic injury via inhibition of recruitment of peripheral inflammatory cells into ischemic brain lesion. A3AR agonists, however, are known to possess anti-platelet activity, which may deter the combination therapy with tissue plasminogen activator for the therapy of cerebral ischemic stroke. Thus, the present study investigates the neuroprotective/anti-ischemic effect of a synthetic seco-nucleoside, LMT497 ((S)-2-((R)-1-(2-chloro-6-(3-iodobenzylamino)-9H-purin-9-yl)-2-hydroxyethoxy)-3-hydroxy-N-methylpropanamide) with little anti-platelet activity. LMT497 neither showed A3AR binding activity nor anti-platelet activity. In our present study LMT497 significantly attenuated the injury/death of cortical neurons exposed to oxygen-glucose deprivation (OGD) followed by re-oxygenation (R). LMT497 significantly reduced the ascending cellular level of reactive oxygen species under ischemic conditions by increasing the superoxide dismutase (SOD) levels. LMT497 also inhibited the migration of microglia which mediates inflammatory responses in ischemia. In rats subjected to middle cerebral artery occlusion (MCAO, 1.5 h) followed by reperfusion, LMT497 largely reduced brain infarction volume, and edema, and improved neurological score. Therapeutic efficacy of LMT497 was obtained by twice treatments even at 10 h and 18 h after the onset of ischemia. Collectively, LMT497 could be a therapeutic drug candidate with a wide therapeutic time window for the treatment of cerebral ischemic stroke.
